Researchers are exploring new engineering strategies to improve the safety and effectiveness of CAR T-cells, which are being investigated for their potential to treat various conditions, including solid tumors and cancer. The development of next-generation CAR T-cell therapies may involve the use of technologies such as automation and AI, as well as innovative approaches like in vivo site-specific engineering and the use of fusion proteins. These advancements aim to enhance the potential of CAR T-cells to target specific diseases, including prostate cancer, and potentially expand their application beyond cancer treatment.